Clinical Trial Update: The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients [Phase 1]

View source ↗

Summary

This Phase 1 study reports safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-523 in patients with immune thrombocytopenia, with the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• HMPL-523

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Immune Thrombocytopenia (ITP) | Phase 1 | Status: COMPLETED